Cure For Cancer: Novartis Drug Zykadia Beats Chemotherapy In Lung Cancer Patients

Swiss drugmaker Novartis AG reported reported dramatic results Wednesday among late-stage lung cancer patients with its gene-inhibiting drug Zykadia.

Novartis said Zykadia more than doubled the median progression-free survival rate to 16.6 months, compared to 8.1 months for traditional chemotherapy patients, suffering from anaplastic lymphoma kinase-positive nonsmall cell lung cancer.